Semaglutide: observed

146 studies: patients on it are followed, or it is given outside a trial. Page 1 of 2. Open to participants first (57), then studies with results posted, then the rest; newest registration first within each.

• Ocular Changes in Patients Using Tirzepatide or SemaglutideRecruitingNCT07924618Report a problem
• Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent ObesityNot yet recruitingNCT07911046Report a problem
• Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With ObesityRecruitingNCT07901777Report a problem
• A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapyNot yet recruitingNCT07881783Report a problem
• Semaglutide Health Outcomes and Patient Adherence in AustraliaNot yet recruitingNCT07881770Report a problem
• GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without DiabetesRecruitingNCT07858864Report a problem
• NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World StudyNot yet recruitingNCT07846956Report a problem
• GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF RegistryNot yet recruitingNCT07787936Report a problem
• Comparing Facial Aging Between Identical Twins With 3D ImagingNot yet recruitingNCT07760532Report a problem
• Salivary Function and Dental Changes During GLP-1 TherapyNot yet recruitingNCT07720466Report a problem
• Effects of GLP-1 RAs on Human Lactation OutcomesRecruitingNCT07720414Report a problem
• Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor AgonistsRecruitingNCT07702461Report a problem
• Imaging in Semaglutide StudyRecruitingNCT07695454Report a problem
• GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid ObesityNot yet recruitingNCT07668765Report a problem
• Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.RecruitingNCT07653412Report a problem
• Estimating the Impact of Obesity Medications on Clinical and Economic OutcomesEnrolling by invitationNCT07640139Report a problem
• Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated HemoglobinRecruitingNCT07621419Report a problem
• Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and ObesityRecruitingNCT07605572Report a problem
• GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort StudyNot yet recruitingNCT07588984Report a problem
• A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in ChinaEnrolling by invitationNCT07456774Report a problem
• Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical ClockNot yet recruitingNCT07444073Report a problem
• Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated ObesityNot yet recruitingNCT07423481Report a problem
• A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque PsoriasisNot yet recruitingNCT07382388Report a problem
• The Effect of Semaglutide on the Intestinal Flora in ObesityNot yet recruitingNCT07323134Report a problem
• Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKDRecruitingNCT07309094Report a problem
• Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical PracticeRecruitingNCT07302802Report a problem
• WEgovy Real World Assessment of Weight Loss in KoreaEnrolling by invitationNCT07280221Report a problem
• Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric RetentionNot yet recruitingNCT07276763Report a problem
• Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle MassRecruitingNCT07272837Report a problem
• Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss PatientsRecruitingNCT07229170Report a problem
• People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 AgonistsRecruitingNCT07207148Report a problem
• Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKDRecruitingNCT07187830Report a problem
• Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)RecruitingNCT07169136Report a problem
• Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric RetentionNot yet recruitingNCT07156591Report a problem
• Research on Effects of Drugs on Body Composition and Function With Imaging in DiabetesNot yet recruitingNCT07156331Report a problem
• Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.Enrolling by invitationNCT07154238Report a problem
• Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility ScoresNot yet recruitingNCT07152756Report a problem
• A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical PracticeEnrolling by invitationNCT07055607Report a problem
• Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in ObesityRecruitingNCT07042672Report a problem
• 24-h Energy Expenditure and Anti-obesity MedicationEnrolling by invitationNCT07041983Report a problem
• A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in KoreaEnrolling by invitationNCT07018544Report a problem
• Gastric Emptying in Healthy Volunteers and GLP-1 Agonist UsersNot yet recruitingNCT06987669Report a problem
• Mitigation of Cardiovascular Disease Risks in Children With Extreme ObesityRecruitingNCT06967389Report a problem
• Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.Not yet recruitingNCT06856928Report a problem
• Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)RecruitingNCT06821919Report a problem
• Comprehensive Clinical Evaluation Study of GLP-1RARecruitingNCT06686134Report a problem
• GLP_1 RA Ultrasound StudyEnrolling by invitationNCT06581120Report a problem
• A Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic ObesityRecruitingNCT06380426Report a problem
• The Effect of Semaglutide on Cardiovascular Markers and Liver FunctionRecruitingNCT06301191Report a problem
• Retrospective Analysis for Patients With Metabolic SyndromeRecruitingNCT06182618Report a problem
• Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist TreatmentRecruitingNCT06069622Report a problem
• A Study to Evaluate Safety of Exposure to Wegovy During PregnancyEnrolling by invitationNCT05872022Report a problem
• Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNot yet recruitingNCT05714683Report a problem
• Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaEnrolling by invitationNCT05689372Report a problem
• A Study to Evaluate the Safety of Exposure to Wegovy During PregnancyEnrolling by invitationNCT05503927Report a problem
• Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.RecruitingNCT05419726Report a problem
• BESTMED: Observational Evaluation of Second Line Therapy Medications in DiabetesRecruitingNCT05161429Report a problem
• Body Surface Gastric Mapping in Patients on SemaglutideCompletedNCT06401746Results postedReport a problem
• Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 InhibitorsCompletedNCT05768945Results postedReport a problem
• Metabolic Effects of Switching From Injectable Semaglutide to TirzepatideActive, not recruitingNCT07889453Report a problem
• Real-World Patient and Physician Experience With Semaglutide Across Six Emerging MarketsCompletedNCT07850765Report a problem
• Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/ObesityCompletedNCT07701005Report a problem
• GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial EmulationWithdrawnNCT07677865Report a problem
• Weight Loss in Adults Using Semaglutide (Real-world Study)CompletedNCT07627074Report a problem
• Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.CompletedNCT07619508Report a problem
• Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular RiskCompletedNCT07619495Report a problem
• Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)Active, not recruitingNCT07457424Report a problem
• Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic OutcomesCompletedNCT07424430Report a problem
• INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)CompletedNCT07417618Report a problem
• Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)CompletedNCT07390110Report a problem
• Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep ApneaCompletedNCT07281196Report a problem
• WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. AdultsCompletedNCT07216651Report a problem
• Coronary Flow Reserve Changes After Semaglutide TreatmentCompletedNCT07190144Report a problem
• Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)Active, not recruitingNCT07188545Report a problem
• A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real WorldCompletedNCT07141914Report a problem
• Comparison of Body Composition Changes With Weight Loss InterventionsActive, not recruitingNCT07115069Report a problem
• Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular RiskCompletedNCT07096063Report a problem
• A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).TerminatedNCT07081178Report a problem
• Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes MellitusCompletedNCT07056803Report a problem
• Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D LevelsCompletedNCT07043361Report a problem
• Semaglutide Effectiveness in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease in the Real World PracticeActive, not recruitingNCT06983171Report a problem
• Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection FractionActive, not recruitingNCT06980623Report a problem
• Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection FractionCompletedNCT06914141Report a problem
• Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims DataCompletedNCT06914102Report a problem
• Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real WorldCompletedNCT06874751Report a problem
• Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin ResistanceCompletedNCT06856291Report a problem
• Sleeve Gastrectomy Vs. Lifestyle & Medications: Impact on BMI Trajectory and Target Attainment in a Matched Cohort StudyCompletedNCT06820047Report a problem
• Study of Patients Being Treated With Anti-obesity MedicationActive, not recruitingNCT06790160Report a problem
• Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesCompletedNCT06779929Report a problem
• A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight LossCompletedNCT06761703Report a problem
• Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare ClaimsCompletedNCT06659744Report a problem
• Emulation of the SOUL Diabetes Trial in Healthcare ClaimsCompletedNCT06659718Report a problem
• Emulating the PIONEER6 Diabetes Trial Using Healthcare ClaimsCompletedNCT06659679Report a problem
• Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 DiabetesCompletedNCT06507475Report a problem
• Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective SurgeryCompletedNCT06500143Report a problem
• A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This TreatmentCompletedNCT06478550Report a problem
• CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist UsersActive, not recruitingNCT06467604Report a problem
• The Semaglutide StudyActive, not recruitingNCT06420739Report a problem
• The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.WithdrawnNCT06354101Report a problem
• Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)CompletedNCT06351748Report a problem

← Semaglutide